A venture capital investor warns that Europe’s slate of regulatory reforms will do little to shift investment decisions ...
Agilent’s $240m Proscia deal targets a digital pathology market split in two — clinical labs still largely on glass, biopharma already on screens — with companion diagnostics the clearest near-term ...
The big players have jockeyed into position through business development and are ramping up clinical trial programs with the goal of changing the standard of care in cancer.
UK government confirms support for continued acceptance of CE-marked medical devices in Great Britain on a long-term basis.
Sovereign AI and trusted research environments are quietly reshaping how pharma companies access and analyze data.
As China’s new cosmetics safety standard starts a compliance clock for brands, cosmetic chemist Kelly Dobos explains in an ...
The FDA retired the Chief Information Officer title, but Sanjay Sahoo moved to temporarily lead the new Office of Mission ...
Women’s sports organizations support their athletes’ health and fitness to extend their careers, but research is limited on ...
At recent CRN conference, USANA chief scientific officer Kathryn Armstrong says the firm uses six-point check list to ...
Data from the ARC-20 platform study drive optimism for the Phase III program as the company touts favorable efficacy numbers ...
A white paper on “Digitally Derived Measures” stresses that the process of incorporating them into clinical trials must start ...
Oncology leaders say they’ve learned how to better design and differentiate newer versions of antibody-drug conjugates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results